Latest Headlines
-
Waters Launches Charge Detection Mass Spectrometry Technology To Accelerate The Development Of Next-Generation Biotherapeutics
10/13/2025
Waters Corporation (NYSE: WAT) today unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterization for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.
-
Roche's Elecsys® pTau181 Becomes The Only FDA-Cleared Blood Test For Use In Primary Care To Rule Out Alzheimer's-Related Amyloid Pathology
10/13/2025
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States Food and Drug Administration (FDA) has cleared its Elecsys pTau181 test, the only blood-based biomarker (BBM) test indicated as an aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting.
-
Breakthrough In Blood Test For Alzheimer's By University Of York Researchers
10/9/2025
Researchers have made a significant breakthrough in the development of a blood test for Alzheimer’s, creating a new sensor design that is ultra-sensitive, outperforms competing technologies and can be built into a handheld device.
-
Cost-Efficient And Proven Solution For Sample Testing
10/9/2025
Developed to meet the highest standards in sample integrity, Micronic’s Non-Coded and Alphanumeric Coded tubes provide laboratories worldwide with reliable, durable, and contamination-free solutions for accurate testing.
-
Bluejay Diagnostics And SanyoSeiko Expand Strategic Partnership To Advance Commercialization Of Symphony Platform
10/9/2025
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), a medical diagnostics company focused on developing rapid near-patient testing solutions for critical care, today announced that it has entered into an Agreement to Amend the Master Service Agreement and the Master Supply Agreement with SanyoSeiko Co., Ltd. (“SanyoSeiko”), a Japan-based contract manufacturer specializing in medical devices and precision engineering.
-
Kidney Test Being Developed For Early Intervention And Easy Monitoring
10/8/2025
A simple blood test could reveal kidney disease earlier so more can be done to halt progression, while also allowing better ongoing management of kidney health by simpler monitoring.
-
BD And Opentrons Collaborate To Accelerate Single-Cell Multiomics Discoveries With Robotic Automation
10/8/2025
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recognized worldwide for accessible lab automation with more than 10,000 robotic systems deployed, today announced a multi-year collaboration.
-
CND Life Sciences Is Granted FDA Breakthrough Device Designation For Its Skin Biopsy-Based Syn-One Test®
10/7/2025
CND Life Sciences, Inc. (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for the company's Syn-One Test® for aiding the diagnosis of synucleinopathies in patients aged 40 years and older with neurologic conditions that present with clinical features suggestive of a synucleinopathy.
-
PacBio Expands Partnership With seqWell To Bring Scalable Long Read Sample Prep To More Labs
10/7/2025
PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced an expanded partnership with seqWell, a global provider of genomic library and multiplexing workflow solutions.
-
Countable Labs Launches Revolutionary Ten-Color PCR Platform, Bridging The Gap Between PCR And Next-Generation Sequencing Technologies
10/7/2025
Countable Labs, the developer of Countable PCR, a category-defining PCR technology that sets a new benchmark for sensitivity in genomics, announced the launch of Countable 10, the first and only PCR platform capable of 10-color multiplexing.